Search
Doxapram
go.drugbank.com/drugs/DB00561ApprovedInvestigationalVet approvedA central respiratory stimulant with a brief duration of action. (From Martindale, The Extra Pharmocopoeia, 30th ed, p1225)
Categories: Heterocyclic Compounds, 1-RingSynonyms: 1-ethyl-4-(2-morpholinoethyl)-3,3-diphenyl-2-pyrrolidinoneDexrazoxane
go.drugbank.com/drugs/DB00380ApprovedInvestigationalWithdrawnIt appears to inhibit formation of a toxic iron-anthracycline complex.
Categories: Heterocyclic Compounds, 1-Ring, Compounds used in a research, industrial, or household settingSynonyms: 4-[(2S)-2-(3,5-dioxopiperazin-1-yl)propyl]piperazine-2,6-dione, 2,6-Piperazinedione, 4, 4'-(1-methyl-1,2-ethanediyl)bis-, (S)- (9CI)Empagliflozin
go.drugbank.com/drugs/DB09038ApprovedInvestigational[A203501] Attempts at overcoming these limitations first saw the development of O-glucoside analogs of phlorizin (e.g. … Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney.
Mixtures: GLYXAMBI® 25 MG/ 5 MG, GLYXAMBI® 25 MG/ 5 MGCategories: P-glycoprotein substrates, Sodium-Glucose Transporter 2 InhibitorsCeftazidime
go.drugbank.com/drugs/DB00438ApprovedInvestigational[L32935] Ceftazidime was approved by the FDA on July 19, 1985, and is currently available either alone or in combination with the non-β-lactam β-lactamase inhibitor [avibactam] to treat a variety of … Bacteria possess a cell wall comprising a glycopeptide polymer commonly known as peptidoglycan, which is synthesized and remodelled through the action of a family of enzymes known as "penicillin-binding
Mixtures: CEFAZIME FOR INJECTION 1 g/vial, ZAVİCEFTA 2 G/0.5 G İNFÜZYONLUK ÇÖZELTİ HAZIRLAMAK İÇİN TOZ, 10 ADETCategories: Heterocyclic Compounds, 2-RingDexchlorpheniramine maleate
go.drugbank.com/drugs/DB09555ApprovedDexchlorpheniramine is the S-enantiomer of chlorpheniramine which is a 1st generation anti-histamine. … Dexchlorpheniramine has more pharmacological activity than the R and so is more potent than the racemic mixture.
Mixtures: Rescon MX, HUFADEXTA-MCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 InhibitorsOmega-3 fatty acids
go.drugbank.com/drugs/DB11133ApprovedInvestigationalNutraceuticalOmega-3 fatty acids play a critical role in metabolism and cellular function and they are available as daily supplements. On September 8, 2004, the U.S. … fish oil that originally come from microalgae that is further consumed by phytoplankton, a source of diet for fish).
Synonyms: n-3 PUFAs, n-3 fatty acidsMixtures: Lipidem 200mg/ml Emulsion for Infusion, PR Natal 400 ecMetyrapone
go.drugbank.com/drugs/DB01011ApprovedInvestigationalIt is used as a test of the feedback hypothalamic-pituitary mechanism in the diagnosis of cushing syndrome.
Categories: Cytochrome P-450 CYP2A6 Inhibitors, Cytochrome P-450 CYP3A InducersProducts: Metycor 250 mg WeichkapselnFingolimod
go.drugbank.com/drugs/DB08868ApprovedInvestigationalMultiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. … It was developed by Novartis and initially approved by the FDA in 2010.[L12651] Fingolimod was also studied for the treatment of COVID-19, the disease caused by infection with the SARS-CoV-2 virus.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2E1 SubstratesProducts: FINGOLIMOD EG, LEBRINA® 0.5 MGHydroxychloroquine
go.drugbank.com/drugs/DB01611ApprovedInvestigationalHydroxychloroquine is a racemic mixture consisting of an R and S enantiomer.[A183047] Hydroxychloroquine is an aminoquinoline like [chloroquine]. … [L8072] A recent study reported a fatality in the group being treated with hydroxychloroquine for COVID-19.[A192546]
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 SubstratesSynonyms: 2-(N-(4-(7-chlor-4-chinolylamino)-4-methylbutyl)ethylamino)ethanol, 7-chloro-4-(4-(N-ethyl-N-β-hydroxyethylamino)-1-methylbutylamino)quinolineCarbidopa
go.drugbank.com/drugs/DB00190ApprovedInvestigationalCarbidopa presents a chemical denomination of N-amino-alpha-methyl-3-hydroxy-L-tyrosine monohydrate. … therapy developed by Mayne Pharma in 1992.
Mixtures: CARBIDOPA X 25 MG Y LEVODOPA X 250 MG, CARBIDOPA X 25 MG Y LEVODOPA X 250 MGCategories: Aromatic L-amino Acid Decarboxylase Inhibitors